Literature DB >> 9809975

BAX expression is associated with enhanced intracellular accumulation of paclitaxel: a novel role for BAX during chemotherapy-induced cell death.

T Strobel1, S K Kraeft, L B Chen, S A Cannistra.   

Abstract

SW626 cells that overexpress BAX are sensitized to the cytotoxic effects of paclitaxel and vincristine. It has been assumed that BAX mediates these effects through its ability to alter mitochondrial function, specifically by promoting the release of cytochrome c and facilitating the mitochondrial permeability transition. However, we have found that several early paclitaxel-mediated events are enhanced in SW626 transfectants that overexpress BAX, including G2-M-phase arrest, tubulin polymerization, and BCL-2 phosphorylation. We now demonstrate that these seemingly disparate effects are explained by an enhanced accumulation of paclitaxel in BAX-overexpressing cells, an effect due to diminished drug efflux. In contrast, drug efflux is increased in cells that do not overexpress BAX, resulting in low intracellular paclitaxel levels and relative resistance to the effects of this drug. Drug efflux in SW626 cells is mediated by a verapamil-inhibitable, non-MDR-1, non-MRP-1 transporter whose function or expression may be inhibited by BAX. These data suggest that stable transfectants that overexpress BAX may be sensitized to apoptotic cell death through a novel mechanism involving the enhancement of intracellular levels of naturally occurring toxins such as alkaloid derivatives.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9809975

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

1.  Suppression of P-gp induced multiple drug resistance in a drug resistant gastric cancer cell line by overexpression of Fas.

Authors:  Fang Yin; Yong-Quan Shi; Wei-Ping Zhao; Bing Xiao; Ji-Yan Miao; Dai-Ming Fan
Journal:  World J Gastroenterol       Date:  2000-10       Impact factor: 5.742

2.  Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342.

Authors:  Lyndsay N Harris; Gloria Broadwater; Nancy U Lin; Alexander Miron; Stuart J Schnitt; David Cowan; Jonathan Lara; Ira Bleiweiss; Donald Berry; Matthew Ellis; Daniel F Hayes; Eric P Winer; Lynn Dressler
Journal:  Breast Cancer Res       Date:  2006       Impact factor: 6.466

3.  Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2.

Authors:  M Schuyer; M E van der Burg; S C Henzen-Logmans; J H Fieret; J G Klijn; M P Look; J A Foekens; G Stoter; E M Berns
Journal:  Br J Cancer       Date:  2001-11-02       Impact factor: 7.640

4.  Effect of non-steroidal anti-inflammatory drugs on colon carcinoma Caco-2 cell responsiveness to topoisomerase inhibitor drugs.

Authors:  P Ricchi; T Di Matola; G Ruggiero; D Zanzi; A Apicella; A di Palma; M Pensabene; S Pignata; R Zarrilli; A M Acquaviva
Journal:  Br J Cancer       Date:  2002-05-06       Impact factor: 7.640

5.  Bax induction activates apoptotic cascade via mitochondrial cytochrome c release and Bax overexpression enhances apoptosis induced by chemotherapeutic agents in DLD-1 colon cancer cells.

Authors:  T Kobayashi; H Sawa; J Morikawa; W Zhang; H Shiku
Journal:  Jpn J Cancer Res       Date:  2000-12

6.  Geridonin and paclitaxel act synergistically to inhibit the proliferation of gastric cancer cells through ROS-mediated regulation of the PTEN/PI3K/Akt pathway.

Authors:  Sai-Qi Wang; Cong Wang; Li-Ming Chang; Kai-Rui Zhou; Jun-Wei Wang; Yu Ke; Dong-Xiao Yang; Hong-Ge Shi; Ran Wang; Xiao-Li Shi; Li-Ying Ma; Hong-Min Liu
Journal:  Oncotarget       Date:  2016-11-08

7.  The Syk inhibitor R406 is a modulator of P-glycoprotein (ABCB1)-mediated multidrug resistance.

Authors:  George E Duran; Branimir I Sikic
Journal:  PLoS One       Date:  2019-01-22       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.